We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
51
Rhythm Pharmaceuticals
RYTM
$7.42B
$27.3M 0.54%
314,100
+74,300
+31% +$7.23M
TMO icon
52
Thermo Fisher Scientific
TMO
$230B
$22.9M 0.45%
46,500
– –
SNDX icon
53
Syndax Pharmaceuticals
SNDX
$1.74B
$22.5M 0.45%
+962,300
New +$20.9M
BTSG icon
54
BrightSpring Health Services
BTSG
$11.7B
$21.2M 0.42%
497,800
+9,300
+2% +$375K
LXEO icon
55
Lexeo Therapeutics
LXEO
$392M
$20.7M 0.41%
3,602,450
+1,477,450
+70% +$10.5M
STRO icon
56
Sutro Biopharma
STRO
$339M
$20M 0.4%
+801,144
New +$14.5M
NKTR icon
57
Nektar Therapeutics
NKTR
$2.43B
$19.8M 0.39%
+275,000
New +$15.7M
HELP
58
Cybin Inc
HELP
$891M
$18.4M 0.36%
3,832,843
-7,657
-0.2% -$49.5K
KRYS icon
59
Krystal Biotech
KRYS
$10.4B
$17.8M 0.35%
69,100
-50,700
-42% -$13.5M
PVLA
60
Palvella Therapeutics
PVLA
$2.15B
$16.8M 0.33%
+134,600
New +$14M
CRBP icon
61
Corbus Pharmaceuticals
CRBP
$214M
$16.3M 0.32%
1,737,287
+140,000
+9% +$1.18M
URGN icon
62
UroGen Pharma
URGN
$2.14B
$15.7M 0.31%
875,487
– –
DFTX
63
Definium Therapeutics
DFTX
$5.5B
$15.2M 0.3%
804,000
-422,700
-34% -$7.17M
VERA icon
64
Vera Therapeutics
VERA
$2.44B
$14.9M 0.29%
369,596
+16,096
+5% +$693K
QTTB icon
65
Q32 Bio
QTTB
$453M
$14.5M 0.29%
2,252,987
– –
WHWK
66
Whitehawk Therapeutics
WHWK
$265M
$14.4M 0.28%
4,166,000
– –
AMGN icon
67
Amgen
AMGN
$233B
$14M 0.28%
+39,900
New +$14.2M
ALHC icon
68
Alignment Healthcare
ALHC
$2.86B
$13.9M 0.28%
+791,000
New +$15.9M
EYPT icon
69
EyePoint Inc
EYPT
$378M
$13.8M 0.27%
1,069,147
-1,399,167
-57% -$20.9M
JANX icon
70
Janux Therapeutics
JANX
$1.1B
$13.7M 0.27%
983,600
-970,826
-50% -$13.3M
BCRX icon
71
BioCryst Pharmaceuticals
BCRX
$2.49B
$13.6M 0.27%
1,425,200
-316,600
-18% -$2.46M
BCAX
72
Bicara Therapeutics
BCAX
$1.56B
$13.3M 0.26%
667,300
+458,200
+219% +$7.89M
BIOA
73
BioAge Labs
BIOA
$445M
$12.4M 0.25%
711,811
-79,090
-10% -$1.52M
COGT icon
74
Cogent Biosciences
COGT
$6.01B
$12.4M 0.25%
322,100
-48,900
-13% -$1.81M
ALMS
75
Alumis Inc
ALMS
$2.92B
$12.1M 0.24%
548,163
-554,567
-50% -$13.9M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.